Optimising management of patients with advanced heart failure. The importance of preventing progression

Drugs and Aging

Volumn 16, Issue 2, 2000, Pages 87-106

  Stanek, Brigitte ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT;

HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART TRANSPLANTATION; HEMODYNAMICS; HUMAN; MORTALITY; POLYPHARMACY; PRIORITY JOURNAL; REVIEW; SIDE EFFECT;

EID: 0034007091     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200016020-00002     Document Type: Review

References (108)

1. 1. Remme WJ. Prevention of worsening heart failure: future focus. Eur Heart J 1998; 19 Suppl. B: B47-53
2. 2. Garg R, Yusuf S, for the Collaborative Group on ACE-Inhihitor Trials. Overview of randomized trials of angiotensin converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450-6
3. 3. SOLVD Investigators. Effects of enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 1991 ; 325: 293-302
4. 4. Swedberg K, Kjekshus J, Snapinn S, for the CONSENSUS investigators. Long-term survival in severe heart failure patients treated with enalapril. Eur Heart J 1999; 20: 136-9
5. 5. Lechat P, Packer M, Chalon S, et al. Clinical effects of β-adrenergic blockade in chronic heart failure: a meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998; 98: 1184-91
6. 6. Remme WJ. Inodilator therapy for heart failure. Early, late or not at all? Circulation 1993; 87; IV-102-7
7. 7. Stevenson LW. Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Failure 1999; 1: 251-7
8. 8. Dies F. Intermittent dobutamine in ambulatory patients with chronic cardiac failure. Br J Clin Pract 1986; 45 Suppl.: 37-40
9. 9. Califf RM, Adams KF, McKenna WJ, et al. A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997; 134: 44-54
10. 10. Pacher R. Stanek B. Ambulatory vasodilator therapy in heart failure: systematic review of the literature and personal observational experience. Eur J Heart Failure 1999; 1: 263-8
11. 11. Houghton AR, Cowley AJ. Why are ACE-inhibitors underutilized in the treatment of heart failure by general practitioners? Int J Cardiol 1997; 59: 7-10
12. 12. Chin MH, Wang JC, Zhang JX, et al. Utilization and dosing of angiotensin converting enzyme inhibitors for heart failure. J Gen Intern Med 1997; 12: 563-6
13. 13. McMurray JJ. Failure to practice evidence-based medicine: why do physicians not treat patients with heart failure with angiotensin converting enzyme inhibitors? Eur Heart J 1998; 19 Suppl. L: L15-L21
14. 14. Luzier AB, Forrest A, Adelman M, et al. Impact of angiotensin-converting enzyme inhibitor underdosing on rehospitalization rates in congestive heart failure. Am J Cardiol 1998, 82: 465-9
15. 15. Husten L. ATLAS shows global undertreatment of heart failure (news). Lancet 1998; 351; 1035
16. 16. Mair FS, Crowley TS, Bundred PE. Prevalence, aetiology and management of heart failure in general practice. Br J Gen Pract 1996; 46: 77-9
17. 17. Pflugfelder PW, Baird MG, Tonkon MJ, et al. Clinical consequences of angiotensin converting enzyme withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. J Am Coll Cardiol 1993; 22: 1557-63
18. 18. Pacher R, Stanek B, Globits S, et al. Effects of two different enalapril dosages on clinical, hemodynamic and neurohumoral response of patients with severe congestive heart failure. Eur Heart J 1996; 17: 1223-32
19. 19. Van Veldhuisen DJ, Genth-Zoth S. Netzer T, et al. High-versus low ACE-inhibition in patients with chronic heart failure: a placebo-controlled study with imidapril [abstract]. Circulation 1997; 96 Suppl. 8: 120
20. 20. Fowler MB, Vagelos RH, Schröder JS, et al. Comparison of high versus low dose enalapril therapy on clinical outcomes and neuroendocrine activation in advanced heart failure. AHA 70th Sessions. Circulation 1997; 96 Suppl.: 1-20
21. 21. NETWORK Investigators. Clinical outcome with enalapril in symptomatic chronic heart failure; a dose comparison. Eur Heart J 1998; 19: 481-9
22. 22. Packer M, Poole-Wilson P, Armstrong P, et al. Comparative effects of low-dose versus high-dose lisinopril on survival and major events in chronic heart failure: the Assessment of Treatment with Lisinopril and Survival Study (ATLAS) [abstract]. Eur Heart J 1998: 19 Suppl.: 142
23. 23. Cohn JN. Beta-blockers in heart failure. Eur Heart J 1998; 19 Suppl. F: F52-F55
24. 24. Waagstein F, Bristow MR, Swedberg K, et al., for the Metoprolol in Dilated Cardiomyopathy Trial Study Group. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 1993; 342: 1441-6
25. 25. CIBIS I. A randomized trial of β-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994; 90 Pt 1: 1765-73
26. 26. CIBIS II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study (CIBIS II): a randomized trial. Lancet 1999; 353: 9-13
27. 27. International Steering Committee. Rationale, design, and organisation of the Metoprolol CR/XL Randomized intervention Trial in Heart Failure (MERIT-HF). Am J Cardiol 1997; 80 Suppl. 9B: 54J -58J
28. 28. Packer M, Bristow MR, Cohn JN, et al., for the US Carvedilol Heart Failure Study Group. The effect of carvedilol on LV function and mortality in patients with chronic heart failure. N Engl J Med 1996; 334; 1349-55
29. 29. Hash TW, Prisant ML. β-Blocker use in systolic heart failure and dilated cardiomyopathy. J Clin Pharmacol 1997; 37: 7-19
30. 30. Packer M, Cohn JN, on behalf of the Steering Committee and Membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus Recommendations for the Management of Chronic Heart Failure. Am J Cardiol 1999; 83 (2A): 11A-24A
31. 31. Doughty RN. Beta-blockers for advanced heart failure - how far can you go? Eur J Heart Failure 1999; 1: 269-2
32. 32. Bristow MR, Gilbert EM, Abraham WT, et al., for the MOCHA investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996; 94: 2807-16
33. 33. Hall SA, Cigarroa CG, Marcoux L, et al. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with β-adrenergic blockade. J Am Coll Cardiol 1995: 25: 1154-61
34. 34. Waagstein F, Caidahl K, Wallentin I, et al. Long-term β-blockade in dilated cardiomyopathy: effects of short-and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989; 80: 551-63
35. 35. Gheorghiade M, Ferguson D. Digoxin. A neurohormonal modulator in heart failure? Circulation 1991; 84: 2181-6
36. 36. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-33
37. 37. Packer M, Gheorghiade M, Young JB, et al., for the RADIANCE Study. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. N Engl J Med 1993; 329: 1-7
38. 3R. Uretsky BF, Young JB, Shahidi FE, et al. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol 1993; 22: 955-62
39. 39. Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure: the PROMISE study research group. N Engl J Med 1991; 325: 1468-75
40. 40. Massie BM. 15 years of heart failure trials: what have we learned? Lancet 1998; 352 Suppl. 1: 29-33
41. 41. Cody RJ, Kubo SH, Pickworth KK. Diuretic treatment for the sodium retention of congestive heart failure. Arch Intern Med 1994; 154: 1905-14
42. 42. Richardson A, Bayliss J, Scriven AJ, et al. Double-blind comparison of captopril alone against furosemide plus amiloride in mild heart failure. Lancet 1987; 11, 709-11
43. 43. Dahlstrom U, Karlsson E. Captopril and spironolactone therapy for refractory congestive heart failure. Am J Cardiol 1993; 71: 29A-33A
44. 44. Küpper AJ, Fintelman H, Huige MC, et al. Crossover comparison of the fixed combination of hydrochlorothiazide and triamterene and the free combination of furosemide and triamterene in the maintenance treatment of congestive heart failure. Eur J Clin Pharmacol 1986; 30: 342-3
45. 45. Kiyingi A, Field MJ, Pawsey CC, et al. Metolazone and treatment of severe refractory congestive heart failure. Lancet 1990; 335: 29-31
46. 46. Cohn JH, Johnosn G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide-dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-10
47. 47. Gottlieb SS, Dickstein K, Fleck E, et al. Hemodynamic and neurohumoral effects of the angiotensin antagonist losartan in patients with congestive heart failure. Circulation 1993; 88: 1602-9
48. 48. Crozier I, Ikram H, Awan N, et al, for the Losartan Hemodynamic Study Group. Losartan in heart failure: hemodynamic effects and tolerability. Circulation 1995; 91: 691-7
49. 49. Hamroff G, Katz SD, Mancini D, et al. Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation 1999; 99: 990-2
50. 50. Pitt P, Segal P, Martinez FA, et al., on behalf of ELITE study Investigators. Randomised study of losartan vs caplopril in patients over 65 years with heart failure (Evaluation of heart failure in the Elderly Study, ELITE). Lancet 1997; 349: 747-52
51. 51. Yusuf S, Maggioni AP, Held P, et al. Effects of candesartan, enalapril or their combination on exercise capacity, ventricular function, clinical deterioration, and quality of life in heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) [abstract]. Circulation 1997; 96: 1452
52. 52. Rocha R, Chander PN, Khanna K, et al. Mineralcorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 451-8
53. 53. RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (The Randomized Aldactone Evaluation Study, RALES). Am J Cardiol 1996; 78: 902-7
54. 54. Dunkman WB, Johnson GR, Carson PE, et al. Incidence of thromboembolic events in congestive heart failure. Circulation 1993; 87 Suppl. VI: 94-101
55. 55. Al Khadra AS, Salem DN, Rand WM, et al. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J Am Coll Cardiol 1998; 31: 749-53
56. 56. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989; 321: 406-12
57. 57. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure. Lancet 1994; 344: 493-8
58. 58. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricualr arrythmia. N Engl J Med 1995; 333: 77-82
59. 59. Pinto JV, Ramani K, Neelagaru S, et al. Amiodarone therapy in chronic heart failure and myocardial infarction: a review of the mortality trials with special attention to STAT-CHF and the GESICA trials. Prog Cardiovasc Dis 1997; 40: 85-94
60. 60. Waldo AJ, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventirular dysfunction after recent and remote myocardial infarction. Lancet 1996; 349: 7-12
61. 61. Camm AJ, Echt D, Pratt C, et al. Dofetilide in patients with left ventricular dysfunction and either heart failure or acute myocardial infarction: rationale, design and patient characteristics of the DIAMOND studies. Clin Cardiol 1997; 20: 704-10
62. 62. Packer M, O'Connor CM, Ghali JK, et al. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996; 335: 1107-14
63. 63. Cohn HN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: VHeFT III. Circulation 1997; 96: 856-63
64. 64. Levine TB. The design of the Mortality Assessment in Congestive Heart failure trial. Clin Cardiol 1997; 20: 320-6
65. 65. Dzau VJ, Packer M, Lilliy LS, et al. Prostaglandins in severe congestive heart failure. Relation to activation of the reninangiotensin system and hyponatremia. N Engl J Med 1984; 310: 347-52
66. 66. Guazzi M, Pontone G, Agostini P. Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors. Am Heart J 1999; 138: 254-60
67. 67. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992; 20: 549-55
68. 68. Spaulding C, Charbonnier B, Cohen-Solal A, et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double blind, randomized comparative trial. Circulation 1998; 98: 757-65
69. 69. Stanek B, Silberbauer K. Acute and chronic effects of captopril on bicyclo-PGEm, the stable bicyclic endproduct of prostaglandin E2 in essential hypertension. Nephron 1986; 44: 40-5
70. 70. Stanek B, Punzengruber C, Silberhauer K. Increase in bicycloprostaglandin E2 metabolite in congestive heart failure in response to captopril. Clin Cardiol 1989; 12: 97-101
71. 71. Gainer JV, Morrow JD, Loveland A, et al. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998; 339: 1285-92
72. 72. McDonald KM, Mock J, D'Aloa A, et al. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. Circulation 1995; 91: 2043-8
73. 73. Stevenson LW. Tailored therapy to hemodynamic goals for advanced heart failure. Eur J Heart Failure 1999; 1: 251-7
74. 74. Silver MA. Intermittent inotropes for advanced heart failure: inquiring minds want to know. Am Heart J 1999; 138: 191-2
75. 75. Elis A, Bental T, Kimchi O, et al. Intermittent dobutamine treatment in patients with chronic refractory congestive heart failure: a randomized, double-blind, placebo-controlled study. Clin Pharmacol Ther 1998; 63: 682-5
76. 76. Oliva F, Latini R, Politi A, et al., for the DICE (Dobutamina nell' Insufficienza Cardiaca Estrema) Investigators. Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE Multicenter Trial. Am Heart J 1999: 138: 247-53
77. 77. Leier CV, Huss P, Lewis R, et al. Drug-induced conditioning in congestive hart failure. Circulation 1982; 65: 1382-7
78. 78. Stecy P, Gunnar RM. Is intermittent dobutamine infusion useful in the treatment of patients with refractory heart failure? Cardiovasc Clin 1990; 21: 277-89
79. 79. Collins JA, Skidmore MA, Melvin DB, et al. Home intravenous dobutamine therapy in patients awaiting heart transplantation. J Heart Transplant 1990; 9: 205-8
80. 80. Pickworth KK. Long-term dobutamine therapy for refractory congestive heart failure. Clin Pharm 1992; 11: 618-24
81. 81. Dumas D, Cassidy C, Smart FW, et al. Ambulatory use of dobutamine in congestive heart failure. J Transpl Coord 1993; 27-30
82. 82. Miller LW, Merkle EJ, Jennison H. Outpatient use of dobutamine to support patients awaiting heart transplantation. J Heart Lung Transplant 1994; 13: S126-9
83. 83. Ferroni C, Fraticelli A, Paciaroni E. Intermittent dobutamine therapy in patients with advanced congestive heart failure. Arch Gerontol Geriatr 1996, 23: 313-27
84. 84. Sindone AP, Keogh AM, Mcdonald PS, et al. Continuous home ambulatory intravenous inotropic drug therapy in severe heart failure: safety and cost efficacy. Am Heart J 1997; 134: 889-900
85. 85. Moen EK, Young JB. Using outpatient parenteral inotropic therapy for severe congestive heart failure. Cardiol Rev 1997; 5: 305-11
86. 86. Winkel E, Kao W, Fisher SG, et al. Outpatient inotropic therapy in heart transplant candidates: should its use influence waiting list priority status? J Heart Lung Transplant 1998; 17: 809-16
87. 87. Benotti JR, Lesko LJ, McCue HE, et al. Pharmacokinetics and pharmacodynamics of milrinone in chronic congestive heart failure. Am J Cardiol 1985; 56: 685-9
88. 88. Pflugfelder PW, O'Neill BJ, Ogilvie RI, et al. A Canadian multicenter study of a 48h infusion of milrinone in patients with severe heart failure. Can J Cardiol 1991; 7: 5-10
89. 89. Marius-Nunez AL, Heaney L, Fernandez RN, et al Intermittent inotropic therapy in an outpatient setting: a cost-effective therapeutic modality in patients with refractory heart failure. Am Heart J 1996; 132: 805-8
90. 90. Jennison SH, Dhar SC, Derflex MC, et al. Outpatient use of continuous intravenous milrinone for advanced heart failure. Cong Heart Failure; Prev. and Management 1996; Sep/Oct: 15-20
91. 91. Shipley JB, Tolman D, Hastillo A, et al. Milrinone: basic and clinical pharmacology and acute and chronic management. Am J Med Sci 1996; 311 (6): 286-91
92. 92. Mehra MR, Ventura HD, Kapoor C, et al. Safety and clinical utility of long-term intravenous milrinone in advanced heart failure. Am J Cardiol 1997; 80: 61-4
93. 93. Cesario D, Clark J, Maisel A. Beneficial effects of intermittent home administration of the inotrope/vasodilator milrinone in patients with end-stage congestive heart failure: a preliminary study. Am Heart J 1998; 135: 121-9
94. 94. Hatzicharias A, Makris T, Krespi P, et al. Intermittent milrinone effect on long-term hemodynamic profile in patients with severe congestive heart failure. Am Heart J 1999; 138: 241-6
95. 95. O'Connell JB, Gilbert EM, Renlund DG, et al. Enoximone as a bridge to heart transplantation: the Utah experience. J Heart Lung Transplant 1991; 10: 477-81
96. 96. Friedel N, Teebken M, Lemme A, et al. Enoximone as pharmacologic bridging to heart transplantation. Z Kardiol 1991; 80 Suppl. 4: 27-33
97. 97. Loisance DY, Deleuze PH, Houel R, et al. Pharmacologic bridge to cardiac transplantation. Current limitations. Ann Thorac Surg 1993; 55: 310-3
98. 98. Wimmer A, Stanek B, Kubecova L, et al. Effects of prostaglandinE1, dobutamine and placebo on hemodynamic, renal and neurohumoral variables in patients with advanced heart failure. Jpn Heart J 1999, 40: 311-34
99. 99. Stanek B, Sturm B, Frey B. et al. Bridging to heart transplantation: prostaglandin EI versus prostacyclin versus dobutamine. J Heart Lung Transplant 1999; 18: 358-66
100. 100. Paris W, Woodbury A, Thompson S, et al. Returning to work after heart transplantation. J Heart Lung Transplant 1993; 12: 46-54
101. 101. Packer M, Swedberg K, McMurray J, et al. Multicenter, double-blind, placebo-controlled study of long term endothelin blockade with bosentan in chronic heart failure: results of the REACH trial. 71st Scientific Session of the American Heart Association; 1998 Nov 8-11; Dallas
102. 102. Krum H, Charlon V, Widman T, et al. Long-term, open-label experience with an endothelin receptor antagonist bosentan in patients with severe chronic heart failure. Circulation 1999; 100 Suppl. 1: 1-646
103. 103. Deswal A, Bozkurt B, Seta Y, et al. Safety and efficacy of a soluble P75 tumor necrosis factor α receptor (enbrel, etanercept) in patients with advanced heart failure. Circulation 1999; 99: 3224-0
104. 104. Torre-Amione G, Bozkurt B, Deswal A, et al. An overview of tumor necrosis factor α and the failing human heart. Curr Opin Cardiol 1999; 14: 206-10
105. 105. Packer M, Nieminen MS, Hasenfuss C, et al. Effect of intravenous levosimendan, a calcium sensitizer, on the survival of hospitalized patients with heart failure. Circulation 1999; 100 Suppl. I: 1-646
106. 106. Gronda EG, Barbieri P, Frigerio M, et al. Prognostic indices in heart transplant candidates after the first hospitalization triggered by the need for intravenous pharmacologic circulatory support. J Heart Lung Transplant 1999; 18: 654-63
107. 107. Deng MC, Tijan TDT, Asfour B, et al. Left ventricular assist devices - reasons to be enthusiastic. Eur J Heart Failure 1999; 1: 289-91
108. 108. Deng MC, Weyand M, Hammel D, et al. Selection and outcome of left ventricular assist device patients: the Münster experience. J Heart Lung Transplant 1998; 17: 817-25